Everleap Fertility Expands Access to Reproductive Healthcare with New Clinic Opening in The Woodlands, Texas Everleap Fertility, a U.S. fertility care provider formerly known as RMA Houston and part of…
Alpha Cognition Appoints Caren Deardorf to Board of Directors to Support ZUNVEYL Commercial Launch and Pipeline Development Alpha Cognition Inc., a biopharmaceutical company focused on developing and commercializing novel treatments…
Xencor Reports Initial Plamotamab Phase 1b Data Showing Deep B-Cell Depletion and Preliminary Clinical Improvements in Rheumatoid Arthritis Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and…
Corsair Pharma Receives Positive FDA Feedback on TRX-248 Transdermal System Development for Pulmonary Arterial Hypertension Corsair Pharma, Inc., a private, clinical-stage biopharmaceutical company focused on developing innovative prodrug-based transdermal medicines…
101 Therapeutics Presents Phase 2/3 Clinical Data for CD206-Targeted Therapy 101-PGC-005 at ACR Convergence 2026 101 Therapeutics Ltd., a clinical-stage biotechnology company focused on developing macrophage-targeted therapeutics for inflammatory and…
Antech Study Demonstrates KeyScreen GI Parasite PCR Detects Twice as Many Parasite-Positive Samples as Traditional Testing Methods Antech™, a global leader in veterinary diagnostics, has announced the publication of a…
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Advances TA-ERT Toward Planned BLA Submission Spruce Biosciences, a late-stage biopharmaceutical company focused on developing and commercializing innovative treatments for neurological…
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial of Ataciguat, Advances Plans for Aortic Stenosis Development Kardigan®, Inc., a precision cardiovascular company, has announced the completion of enrollment in its…
Bristol Myers Squibb Presents 56-Week SCOUT-HCM Results Supporting Camzyos in Pediatric Patients With Obstructive Hypertrophic Cardiomyopathy Bristol Myers Squibb has announced positive 56-week results from the Phase 3 SCOUT-HCM clinical…
Lenacapavir Achieves Nearly Twice the One-Year Persistence of Daily Oral F/TDF for HIV Prevention Gilead Sciences, has announced positive results from its PURPOSE 5 clinical trial, demonstrating significantly higher persistence…
Obsidian Therapeutics Reports Promising Amsoki-Cel Results in ICI-Resistant Advanced Melanoma, With 67% Response Rate Obsidian Therapeutics, a clinical-stage biopharmaceutical company developing engineered tumor-infiltrating lymphocyte (TIL) cell therapies through its proprietary…
Aulos Bioscience Reports Positive Phase 2 Results for Imneskibart-Based Regimens in Checkpoint Inhibitor-Refractory Melanoma and NSCLC at SITC 2026 Aulos Bioscience, an immuno-oncology company focused on developing innovative immune-activating antibody…